{"": [92, 101, 0, 102, 1382, 0], "Introduction": [1383, 5328, 0], "Overall workflow": [5338, 8072, 0], "Antiviral and anti\u2010inflammatory signatures derived from post\u2010SARS\u2010CoV\u20102 infection transcriptomics": [8073, 11172, 0], "Identification of antiviral and anti\u2010cytokine compounds and corresponding targets": [11173, 13270, 0], "Classification of host proteins implicated in SARS\u2010CoV\u20102 infection in four modules": [13271, 15894, 0], "Prioritization of candidate compounds proposed to have antiviral effects": [15895, 17701, 0], "Prioritization of candidate compounds proposed to have anti\u2010inflammatory effects": [17702, 20056, 0], "Testing the SARS\u2010CoV\u20102 inhibitory properties of prioritized compounds in in\u00a0vitro assays": [20057, 27198, 0], "Results": [5329, 27198, 1], "Utility of the computational pipeline for identifying repurposable drugs": [27211, 31123, 0], "Linsitinib": [32882, 34761, 0], "Imipramine": [34762, 35755, 0], "Brompheniramine": [35756, 36289, 0], "Salmeterol": [36290, 37607, 0], "Ezetimibe": [37608, 38548, 0], "Hexylresorcinol": [38549, 39233, 0], "Rottlerin": [39234, 39755, 0], "Temsirolimus and torin\u20101": [39756, 40918, 0], "Semaxanib": [40919, 41122, 0], "Compounds targeting immune response": [41123, 42428, 0], "Potential mechanisms of action of drug candidates": [31124, 42428, 1], "Autophagy enhancement as a possible mechanism to exploit in combination therapies": [42429, 45618, 0], "Discussion": [27199, 45618, 1], "Evaluation of host\u2010targeted antiviral and anti\u2010hyperinflammatory signature from post\u2010SARS\u2010CoV\u20102 infection transcriptomics": [45642, 48444, 0], "Identification of known compound\u2010target interactions": [48445, 49113, 0], "Prioritizing the predicted compounds using their network proximity": [49114, 51387, 0], "Compound clustering by means of interaction\u2010pattern\u2010based similarities": [51388, 51995, 0], "\nIn vitro viral inhibition assays": [51996, 54274, 0], "Cell culture": [54305, 55247, 0], "Reagents": [55248, 55725, 0], "Transfection of cells for syncytia assay": [55726, 56409, 0], "Cell treatment for High Content Screening": [56410, 57258, 0], "Syncytia assay co\u2010culture, imaging, and analysis": [57259, 58710, 0], "Cell fusion (syncytia) assay": [54275, 58710, 1], "Materials and Methods": [45619, 58710, 1], "Author contributions": [58711, 59324, 0], "Conflict of interests": [59325, 59629, 0], "Supporting information": [59630, 59825, 0]}